{
    "title": "Antiprogestin Testing Act of 1993",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Antiprogestin Testing Act of 1993''.\n\nSEC. 2. INFORMATION.\n\n    (a) Collection.--\n            (1) In general.--The Commissioner of Food and Drugs \n        (referred to in this section as the ``Commissioner'') shall, to \n        the extent possible, collect information with respect to the \n        drug RU-486, also known as Mifeprestone, including samples and \n        specimens, that is required to be submitted by an applicant for \n        approval of a new drug, as described in section 505(b) of the \n        Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(b)).\n            (2) Uses of drug.--The Commissioner shall collect such \n        information regarding--\n                    (A) use of the drug as an abortifacient or \n                contraceptive; and\n                    (B) use of the drug for the treatment of cancer, \n                brain tumors, Cushings syndrome, or other serious or \n                life-threatening diseases.\n    (b) Consideration.--The Commissioner shall consider the information \ncollected under subsection (a) with respect to the drug to be an \napplication, submitted by the manufacturer of the drug, for approval of \nthe drug for each of the uses described in subsection (a)(2).\n    (c) Approval Decision.--\n            (1) In general.--The Commissioner shall review the \n        information collected under subsection (a) as if the \n        information comprised such an application. The Commissioner \n        shall issue an order approving, or refusing to approve, the \n        application with respect to each of the uses in accordance with \n        subsections (c) and (d) of section 505 of such Act.\n            (2) Refusal to approve due to insufficient tests, \n        information, or evidence.--\n                    (A) Notification of director of national institutes \n                of health.--The Commissioner shall notify the Director \n                of the National Institutes of Health (referred to in \n                this section as the ``Director'') if the Commissioner \n                issues an order refusing to approve the application \n                because of--\n                            (i) the lack of inclusion of adequate tests \n                        in the investigation of the drug, as described \n                        in section 505(d)(1) of such Act;\n                            (ii) insufficient information, as described \n                        in section 505(d)(4) of such Act; or\n                            (iii) a lack of substantial evidence, as \n                        described in section 505(d)(5) of such Act.\n                    (B) Information.--On so notifying the Director, the \n                Commissioner shall submit to the Director all \n                information relevant to the decision of the \n                Commissioner to issue such order. Such information \n                shall include a description of the tests that were not \n                included in the investigation, or a description of the \n                information or evidence that was not submitted with the \n                application.\n            (3) Report.--The Commissioner shall prepare, and submit to \n        the Committee on Energy and Commerce of the House of \n        Representatives and the Committee on Labor and Human Resources \n        of the Senate, a report concerning any order issued under \n        paragraph (1).\n    (d) Research.--\n            (1) In general.--If the Commissioner issues an order \n        refusing to approve the application, the Director shall \n        expeditiously conduct or support research (including clinical \n        trials) on RU-486, in order to conduct the tests, or develop \n        the information or evidence, described in subsection (c)(2)(B).\n            (2) Institutional review boards and peer review.--Research \n        conducted or supported under paragraph (1) shall be subject to \n        sections 491 and 492 of the Public Health Service Act (42 \n        U.S.C. 289 and 289a).\n            (3) Results.--The Director shall submit the results of the \n        research to the Commissioner. The Commissioner shall consider \n        the results, along with the information collected under \n        subsection (a) with respect to the drug, to be information \n        submitted by the manufacturer of the drug as described in \n        subsection (b), and shall review, and issue an order approving \n        or refusing to approve, the application for the drug, in \n        accordance with subsection (c).\n    (e) Report.--The Secretary of Health and Human Services shall \nprepare, and submit to the Committee on Energy and Commerce of the \nHouse of Representatives and the Committee on Labor and Human Resources \nof the Senate, a report on the status of research conducted or \nsupported under subsection (d) within 6 months of the date on which the \nCommissioner provides notification under subsection (c)(2)(A), and \nevery 6 months thereafter until the research is completed.\n\nSEC. 3. FEES AND COSTS.\n\n    If the Commissioner issues an order approving an application with \nrespect to the drug RU-486 for a use described in section 2(a)(2), any \nperson who introduces the drug into interstate commerce or delivers the \ndrug for introduction into interstate commerce for such use shall \nreimburse--\n            (1) the Food and Drug Administration for--\n                    (A) the amount indicated in the fee schedule set \n                forth in section 736 of the Federal Food, Drug, and \n                Cosmetic Act; and\n                    (B) the amount of the costs incurred by the \n                Commissioner in complying with section 2(a); and\n            (2) the National Institutes of Health for the amount of any \n        costs incurred by the Director in complying with section 2(d)."
}